Literature DB >> 36225504

Can Cross-Sectional Imaging Reliably Determine Pathological Staging of Right-Sided Colon Cancers and Select Patients for More Radical Surgery or Neo-Adjuvant Treatment?

Florence Shekleton1, Edward Courtney2, Adrian Andreou3, John Bunni2.   

Abstract

Purpose and research question Cross-sectional imaging with CT scanning is the most commonly performed imaging modality to stage right-sided colon cancers. There is increasing evidence for the use of neo-adjuvant chemotherapy in selected patients and debate about the role of complete mesocolic excision (CME) and central vascular ligation (CVL) in the management of locally advanced colon cancers. Predicted tumour stage and the presence of nodal metastases by CT are often used to select patients for neo-adjuvant chemotherapy and those that may benefit from CME. This study aims to compare predicted radiological T and N staging with final pathological T and N staging in elective patients having potentially curative surgery for right-sided colon cancer. Methods A retrospective analysis was carried out of a prospectively gathered database of all patients who had undergone (true) right hemicolectomy between 02/01/13 and 21/05/20. Sensitivity, specificity, positive predictive value, and negative predictive value for CT scanning with regards to the pathological nodal metastases were calculated and analysed. Results The sensitivity and specificity of radiology staging for predicting nodal status were 76.4% and 65.5% respectively. The positive predictive value of CT staging for correctly identifying nodal metastases was 55.3%, with a negative predictive value of 77.3%. Conclusions This large series adds further evidence that CT, even when reviewed by expert GI radiologists, has limited accuracy at identifying lymph node metastases in colon cancer.
Copyright © 2022, Shekleton et al.

Entities:  

Keywords:  cme; colorectal cancer; radiology; staging;  ct

Year:  2022        PMID: 36225504      PMCID: PMC9535614          DOI: 10.7759/cureus.28827

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

There are approximately 42,000 new cases of colorectal cancer diagnosed in the UK every year [1]. Despite the modern era of biological and immunological therapies and advances in radiotherapy, surgery remains the mainstay of treatment in the management of visceral cancers. Recent reports indicate that 80% of all cases of cancer will require operative intervention; in some cases, several times [2]. CT scanning is the most common method used to stage colon cancer within the UK and worldwide. A meta-analysis of 16 studies on the diagnostic accuracy of CT for staging nodal positivity of colon cancer showed a pooled sensitivity and specificity of 71% and 67% respectively [3]. In a more recent study focusing specifically on right-sided cancers, Fernandez et al. reported a sensitivity and specificity of 47% and 71% respectively for correctly predicting nodal disease [4]. Overall, the accuracy of CT for identifying any high-risk feature in right-sided colon cancers (pT3/T4, pN+, or EMVI+) was 62%. The authors concluded that CT may not be sufficient to identify patients pre-operatively who would benefit from either neo-adjuvant chemotherapy or more extensive nodal resection. There is no doubt as to the primacy of mesenteric-based resectional surgery in the management of colon and rectal cancer [5]. With regards to rectal cancer, the use of total mesorectal excision (TME) and MRI for local staging has significantly reduced local recurrence, by accurately predicting patients with high-risk diseases and involved surgical margins. Increasingly, there is a focus on the benefits of selective complete mesocolic excision (CME) for high-risk colon cancers. Introduced by Hohenberger in 2009 [6], CME resonates with TME as it emphasizes strictly anatomical dissection along embryological planes to detach a perfectly intact mesentery with a peritoneal envelope housing the local field of cancer spread in an ontogenetic package. This also incorporates central vascular ligation (CVL) which broadly correlates with D3 lymphadenectomy. Hohenberger demonstrated that adoption of CME was associated with a reduction in rates of local recurrence (LR) rate from 6.5 to 3.6% and increased five-year cancer-related survival from 82.1% to 89.1% from 1978-1984 to 1995-2002 [6]. As it stands, no absolute indications for CME exist. The 2014 Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines for the treatment of colorectal cancer propose that any lymph node metastasis recognised before or during the surgery should undergo D3 lymph node dissection [7]. What is clear, is the importance of understanding the accuracy of CT in terms of correctly identifying involved nodes when planning treatment for patients with right-sided colon cancers in the multidisciplinary team. Herein, we examine our data with a primary outcome of assessing the validity of CT to predict final histology. We then discuss the use of CT staging in patient stratification for CME.

Materials and methods

This was a retrospective analysis of a prospectively gathered database approved by the hospitals’ local audit and service provision department (ID 3576). The database was used to identify all patients who had undergone right hemicolectomy between 02/01/13 and 21/05/20. These are defined as resections up to and including the right branch of the middle colic artery. Extended right hemicolectomy (defined as vascular ligation of the middle colic artery at its origin) and patients having non-curative surgery were excluded. A total of 390 patients were identified from the database. Seven were excluded as they did not have a record of a pre-operative CT scan. Also, 269 patients had TNM staging in the original CT report which had been reviewed by a dedicated consultant gastrointestinal radiologist and had the radiological staging documented at the multi-disciplinary team (MDT) meeting. Of these 13 only contained T staging and 80 had staging which gave two values e.g. T2/3, and 114 had no staging in their pre-operative CT report or MDT. All those without previous staging or staging giving two values were reviewed by a GI radiologist (AA) with nine years of consultant experience and a specialist interest in oncological and gastrointestinal imaging. These images were then staged or committed to one specific integer. The radiologist was blinded to the final histological staging. All CT studies were analysed using axial, coronal and sagittal sequences available at 1.5 mm slice thickness, with the ability to also do multiplanar reformats. A further three patients were then excluded as they had a complete response to neo-adjuvant chemotherapy and had a histological T stage of 0. TNM 7 was used. A total of 380 patients were used for the final data analysis. The full study strategy is shown in Figure 1.
Figure 1

Methods flow chart (CT: Computerised Tomography, COLMDT: Colorectal Multidisciplinary Team Meeting)

Pre-treatment radiological stage was then cross-referenced with the final histopathology stage. SPSS Statistics (IBM Corp., Armonk, NY) was used for all data analysis and statistics.

Results

Of the 380 patients included in the final analysis, 49.7% were male and 50.3% female. Around 88.1% of patients were between 60 and 89 years and 75.2% had a BMI between 20 and 29. Only 3.9% had neo-adjuvant chemotherapy as part of the FOxTROT trial ongoing during the study period and 36.6% had adjuvant chemotherapy. Additionally, 77% of the operations were elective (Table 1).
Table 1

Patient demographic data (n=380)

Demographic Value Frequency %
Gender Male 189 49.7%
  Female 191 50.3%
Age 20-29 1 0.3%
  30-39 7 1.8%
  40-49 4 1.1%
  50-59 26 6.8%
  60-69 62 16.3%
  70-79 154 40.5%
  80-89 119 31.3%
  90-100 7 1.8%
BMI 15-19 13 3.4%
  20-24 138 36.3%
  25-29 148 38.9%
  30-34 72 18.9%
  35-39 19 5.0%
  40-44 6 1.6%
  45-49 3 0.8%
Neoadjuvant chemotherapy Yes 15 3.9%
  No 363 95.5%
  No data 2 0.5%
Adjuvant chemotherapy Yes 139 36.6%
  No 204 53.7%
  No data 37 9.7%
Emergency Yes 88 23%
  No 292 77%
The distribution of cancers by T stage is shown in Table 2, with the majority of resected cancers being T3 tumours (51.3%). Analysis of nodal staging showed that 58.4% of cancers had no evidence of lymph nodes metastases (Table 3).
Table 2

T stage distribution of cancers by pathological stage (n=380)

T stage Frequency Percentage
1 15 3.9
2 39 10.3
3 195 51.3
4 131 34.5
Table 3

Nodal status of patients (n=380)

N stage Frequency Percentage
0 223 58.4
1 92 24.2
2 66 17.4
The sensitivity and specificity of radiology staging for predicating nodal status were 76.4% and 65.5% respectively (Table 4). The receiver operating characteristic (ROC) curve was used to determine the area under the ROC curve (AUC) of 0.706 (Figure 2). The positive predictive value of CT staging for correctly identifying nodal metastases was 55.3%, with a negative predictive value of 77.3%. The sensitivity and specificity for nodal status were only marginally altered when analysing according to BMI (BMI>30 vs BMI<30).
Table 4

Sensitivity and specificity of nodal staging by CT scan (n=380)

Sensitivity = 120/(120+37)=76.4%, Specificity = 126/(126+97)=65.5%

Positive Predictive Value = 120/(120+97) = 55.3%, Negative Predictive Value = 126/(126+37) = 77.3%

 Pathological nodes positivePathological nodes negativeTotal
Radiological nodes positive12097217
Radiological nodes negative37126163
Total157223380
Figure 2

ROC curve and AUC

ROC: receiver operating characteristic; AUC: curve area under the ROC curve

Sensitivity and specificity of nodal staging by CT scan (n=380)

Sensitivity = 120/(120+37)=76.4%, Specificity = 126/(126+97)=65.5% Positive Predictive Value = 120/(120+97) = 55.3%, Negative Predictive Value = 126/(126+37) = 77.3%

ROC curve and AUC

ROC: receiver operating characteristic; AUC: curve area under the ROC curve The accuracy of radiological prediction of T1 tumours on final pathology was 53.3%, T2 tumours 56.4%, T3 tumours 59.5% and T3 tumours 49.6% (Table 5).
Table 5

Accuracy of radiology for predicting pathological T stage (n=380)

 Pathological T Stage 
pT1pT2pT3pT4Total
Radiological predicted T stageRad1n %8 53.3%6 15.4%5 2.6%2 1.5%21 5.5%
Rad2n %7 46.7%22 56.4%54 27.7%10 7.6%93 24.5%
Rad3N %0 0%10 25.6%116 59.5%54 41.2%180 47.4%
Rad4N %0 0%1 2.6%20 10.3%65 49.6%86 22.6%
Total  1539195131380

Discussion

Our data shows that the positive predictive value of CT for identifying involved lymph nodes was 55.3%, meaning that CT was effectively not much better than "a coin toss" to differentiate node positive from node-negative disease. Given that all UK MDTs currently stage colon cancer using CT scanning, the importance of highlighting its limitations is paramount. Limitations It should be noted, that although an experienced gastrointestinal radiologist was used to retrospectively analyse previous imaging, it may have been beneficial to have a second radiologist re-stage all the CT scans and then assess the inter-rater reliability with Cohen’s kappa coefficient. However, given that 269 of the scans were already reviewed prior to this study, the majority of scans had been doubly reviewed in our study. Anyhow, it seems that analysis and comparison by more experienced radiologists may not have improved the lymph node staging from CT. Hong et al. have shown that although differentiation between T2 and T3 improves with experience, evaluation of lymph node involvement does not [8]. A study from the Karolinska institute [9] compared CT and pathology in 94 patients with colon cancers, reviewed by two blinded GI radiologists with >20 years of experience. For nodal metastasis, inter-observer agreement (Cohens Kappa) was 0.72. However, sensitivity for both in detecting lymph node metastasis was 69%. The main discrepancy was the under-staging of lymph node metastasis. The authors here also highlight histopathological examinations have shown nearly 50% of lymph nodes in colon cancer are below 5 mm. Large nodes may simply be reactive to inflammation rather than involved by a tumour. This again shows that whilst there may be a good correlation between radiologists, it is the limitation of CT at identifying involved nodes that limits the sensitivity of CT. However, there appears to be no superior alternative imaging modality at present. A Korean study showed the sensitivity and specificity of FDG-PET/CT be inferior to CT for detecting metastases in regional lymph nodes in a cohort of 433 patients undergoing both CT and FDG-PET/CT prior to surgery for colorectal cancer [10]. Nerad et al. [11] evaluated the accuracy of MRI for local staging of colon cancer in 55 patients, with all scans evaluated blindly by two experienced abdominal MRI radiologists. The sensitivity and specificity for detecting nodal involvement (N0 versus N+) were 47% and 86% and 68% and 64% for each radiologist. Despite lymph nodes being clearly visible on diffusion-weighted images, this did not necessarily represent metastatic involvement, with benign nodes also showing high cellularity with high diffuse-weighted images as well. The FOxTROT randomised trial of pre-operative chemotherapy prior to surgical resection of more locally advanced colon cancers focused on the T stage, with the poor prognosis group comprising CT radiological evidence of T4 or T3 disease with ³5mm extramural extension [12]. Pre-operative lymph node staging was not a selection criterion, on the basis of both data from the QUASAR1 study [13], supported by meta-analyses of other trials, indicating the proportional risk reduction in disease recurrence was similar in both node-positive and negative diseases. In fact, of the 354 patients in the control group in the FOxTROT trial who went straight to surgery, 48% were node-negative on their final histology. Conversely, only 6% had T2 disease, highlighting that CT is much better at correctly identifying patients with T3 and T4 diseases. Kotake et al. [14] compared overall survival in a cohort of 6850 Japanese patients with T3 and T4 colon cancers. Patients undergoing a D3 resection had an 18% relative reduction in the risk of death compared to those having a D2 resection. Furthermore, subset analysis showed a greater chance of survival in patients having a D3 compared to D2 resection in node-negative colon cancer. This adds support to the hypothesis that removing the entire mesocolon removes micro-metastases present within the mesentery itself, not confined to lymph nodes or vessels. Chen and Bilchik [15] showed that in patients with node-positive (Dukes C, stage III) colon cancer, their five-year overall survival (OS) increased from 67 to 90% when either 1-10 lymph nodes or more than 40 nodes were removed, respectively in N1 disease. They also showed an improvement in the five-year OS from 51-71% in N2 disease when either less than 35 lymph nodes or greater than 35 nodes were resected, respectively. Hohenberger et al. also reported that in node-negative patients, the five-year survival was significantly greater if 28 or more lymph nodes were removed [6]. Therefore, which group of patients should be offered a CME for right-sided colon cancers? Whilst nodal status is a hard indicator for CME, at least according to the Japanese guidelines, radiology is not a reliable discriminator for node-positive disease. The lack of radiological accuracy and consensus in staging colorectal cancers shown in this study and others means there are insufficient patient stratification methods. More accurate identification pre-operatively of T and N staging would allow selected patients to have neo-adjuvant chemotherapy and more radical surgery to hopefully improve outcomes.

Conclusions

This large series adds further evidence to more limited published series of papers showing that CT, even when reviewed by expert GI radiologists, has limited accuracy at identifying lymph node metastases in colon cancer. More accurate imaging modalities are required to accurately stage tumour factors prior to surgery.
  13 in total

1.  MRI for Local Staging of Colon Cancer: Can MRI Become the Optimal Staging Modality for Patients With Colon Cancer?

Authors:  Elias Nerad; Doenja M J Lambregts; Erik L J Kersten; Monique Maas; Frans C H Bakers; Harrie C M van den Bosch; Heike I Grabsch; Regina G H Beets-Tan; Max J Lahaye
Journal:  Dis Colon Rectum       Date:  2017-04       Impact factor: 4.585

2.  Morphological predictors for lymph node metastases on computed tomography in colon cancer.

Authors:  Erik Rollvén; Lennart Blomqvist; Emma Öistämö; Fredrik Hjern; György Csanaky; Mirna Abraham-Nordling
Journal:  Abdom Radiol (NY)       Date:  2019-05

3.  Reliability of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in the nodal staging of colorectal cancer patients.

Authors:  Hee Jung Yi; Kyung Sook Hong; Nara Moon; Soon Sup Chung; Ryung-Ah Lee; Kwang Ho Kim
Journal:  Ann Coloproctol       Date:  2014-12-31

4.  Locoregional CT staging of colon cancer: does a learning curve exist?

Authors:  Eun Kyoung Hong; Francesca Castagnoli; Nicolo Gennaro; Federica Landolfi; Carlos Perez-Serrano; Ieva Kurilova; Sander Roberti; Regina Beets-Tan
Journal:  Abdom Radiol (NY)       Date:  2020-07-30

Review 5.  Global cancer surgery: delivering safe, affordable, and timely cancer surgery.

Authors:  Richard Sullivan; Olusegun Isaac Alatise; Benjamin O Anderson; Riccardo Audisio; Philippe Autier; Ajay Aggarwal; Charles Balch; Murray F Brennan; Anna Dare; Anil D'Cruz; Alexander M M Eggermont; Kenneth Fleming; Serigne Magueye Gueye; Lars Hagander; Cristian A Herrera; Hampus Holmer; André M Ilbawi; Anton Jarnheimer; Jia-Fu Ji; T Peter Kingham; Jonathan Liberman; Andrew J M Leather; John G Meara; Swagoto Mukhopadhyay; Shilpa S Murthy; Sherif Omar; Groesbeck P Parham; C S Pramesh; Robert Riviello; Danielle Rodin; Luiz Santini; Shailesh V Shrikhande; Mark Shrime; Robert Thomas; Audrey T Tsunoda; Cornelis van de Velde; Umberto Veronesi; Dehannathparambil Kottarathil Vijaykumar; David Watters; Shan Wang; Yi-Long Wu; Moez Zeiton; Arnie Purushotham
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

6.  Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer.

Authors:  Kenjiro Kotake; Tomoka Mizuguchi; Konosuke Moritani; Osamu Wada; Heita Ozawa; Izumi Oki; Kenichi Sugihara
Journal:  Int J Colorectal Dis       Date:  2014-05-06       Impact factor: 2.571

7.  How Reliable Is CT Scan in Staging Right Colon Cancer?

Authors:  Laura M Fernandez; Albert J Parlade; Elliot J Wasser; Giovanna Dasilva; Rafael U de Azevedo; Cinthia D Ortega; Rodrigo O Perez; Angelita Habr-Gama; Mariana Berho; Steven D Wexner
Journal:  Dis Colon Rectum       Date:  2019-08       Impact factor: 4.585

8.  Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome.

Authors:  W Hohenberger; K Weber; K Matzel; T Papadopoulos; S Merkel
Journal:  Colorectal Dis       Date:  2009-11-05       Impact factor: 3.788

9.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Authors:  Toshiaki Watanabe; Michio Itabashi; Yasuhiro Shimada; Shinji Tanaka; Yoshinori Ito; Yoichi Ajioka; Tetsuya Hamaguchi; Ichinosuke Hyodo; Masahiro Igarashi; Hideyuki Ishida; Soichiro Ishihara; Megumi Ishiguro; Yukihide Kanemitsu; Norihiro Kokudo; Kei Muro; Atsushi Ochiai; Masahiko Oguchi; Yasuo Ohkura; Yutaka Saito; Yoshiharu Sakai; Hideki Ueno; Takayuki Yoshino; Narikazu Boku; Takahiro Fujimori; Nobuo Koinuma; Takayuki Morita; Genichi Nishimura; Yuh Sakata; Keiichi Takahashi; Osamu Tsuruta; Toshiharu Yamaguchi; Masahiro Yoshida; Naohiko Yamaguchi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2015-03-18       Impact factor: 3.402

10.  Resectional surgery for malignant disease of abdominal digestive organs is not surgery of the organ itself, but also that of the mesenteric organ.

Authors:  J Bunni; J C Coffey; M F Kalady
Journal:  Tech Coloproctol       Date:  2020-04-02       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.